Morgan Stanley Downgrades Illumina to Underweight with Price Target $110.00

Brokerage firm Morgan Stanley Downgrades its rating on Illumina(NASDAQ:ILMN). In a research note issued to the investors, the brokerage major Lowers the price-target to $110.00 per share. The shares have been rated Underweight. The rating by Morgan Stanley was issued on Jul 5, 2016.

In a different note, CL King said it Initiates Coverage on Illumina, according to a research note issued on Jun 22, 2016. The shares have been rated ‘Buy’ by the firm. On May 4, 2016, Citigroup said it Maintains its rating on Illumina. In the research note, the firm Lowers the price-target to $210.00 per share. The shares have been rated ‘Buy’ by the firm. On May 3, 2016, Morgan Stanley said it Maintains its rating on Illumina. In the research note, the firm Lowers the price-target to $140.00 per share. The shares have been rated ‘Equal-weight’ by the firm. On May 3, 2016, Nomura said it Maintains its rating on Illumina. In the research note, the firm Lowers the price-target to $210.00 per share. The shares have been rated ‘Buy’ by the firm. On Apr 19, 2016, Barclays said it Maintains its rating on Illumina. In the research note, the firm Lowers the price-target to $175.00 per share. The shares have been rated ‘Equal-weight’ by the firm. On Apr 19, 2016, Morgan Stanley said it Maintains its rating on Illumina. In the research note, the firm Lowers the price-target to $160.00 per share. The shares have been rated ‘Equal-weight’ by the firm.

Illumina (ILMN) made into the market gainers list on Fridays trading session with the shares advancing 0.85% or 1.19 points. Due to strong positive momentum, the stock ended at $141.25, which is also near the day’s high of $142.08. The stock began the session at $141.12 and the volume stood at 9,78,166 shares. The 52-week high of the shares is $242.37 and the 52 week low is $127.1. The company has a current market capitalization of $20,792 M and it has 14,72,00,000 shares in outstanding.

Illumina(ILMN) last announced its earnings results on May 3, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $571.76M. Analysts had an estimated revenue of $596.12M. Earnings per share were $0.71. Analysts had estimated an EPS of $0.79.

Several Insider Transactions has been reported to the SEC. On Jun 17, 2016, A Blaine Bowman (director) sold 5,000 shares at $135.17 per share price.Also, On Jun 15, 2016, Christian O Henry (EVP & Chief Commercial Officer) sold 2,141 shares at $138.10 per share price.On Jun 15, 2016, Roy A Whitfield (director) sold 3,800 shares at $140.44 per share price, according to the Form-4 filing with the securities and exchange commission.

Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *